Dendreon, Geron jobs cut after Valeant, Janssen deals
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals pulled Dendreon out of bankruptcy by acquiring the troubled prostate cancer immunotherapy company, and Johnson & Johnson's Janssen Biotech subsidiary pumped much-needed cash into Geron with a drug development partnership, but because of those deals 95 people at Dendreon and Geron are losing their jobs.
You may also be interested in...
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.